Verve Therapeutics is a genetic medicines company.

Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. It has been purpose-built for the task ahead, with a team of experts in cardiovascular medicine, human genetics, gene editing, delivery technologies, drug development, and commercialization.

Verve Therapeutics

Medical Director

Medical Director, Clinical Development

smalldoorvet

immuneering

Medical Director Consultant

Immuneering is a bioinformatics company that develops new medicines unlikely to be found by traditional drug discovery methods.

Immuneering is a biopharmaceutical company with an emerging pipeline focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying its deep knowledge of translational bioinformatics to every stage of the drug development process. It has more than a decade of experience in translational bioinformatics and generating insights into drug mechanisms of action and patient treatment responses.

Immuneering

ImmPACT Bio USA is developing novel cell therapies for treating cancer.

ImmPACT Bio USA Inc. is a cell therapy company aiming to develop potent and selective engineered T-cells for the treatment of solid tumors. The Company's technology enables targeting loss-of-gene features of solid tumor cells, sparing normal, healthy tissues.

ImmPACT Bio

FogPharma is a biopharmaceutical firm that develops precision medicines for the vast majority of therapeutic targets.

FogPharma was born from the scientific and entrepreneurial vision of founder Greg Verdine, a pioneer in the discovery and development of new drug classes that ‚Äúdrug the undruggable.‚Äù FogPharma‚Äôs cell-penetrating mini proteins (CPMPs) are a broad new class of medicines that can drug targets beyond the reach of conventional therapeutics. Together with world-leading experts and collaborators in cancer biology and therapy, our team is building a drug discovery powerhouse having passion, knowledge, and creativity to develop fundamentally new cancer treatments. FogPharma derives financial support from a unique syndicate of extraordinary private and institutional investors. FogPharma‚Äôs network of friends includes our founders, employees, investors, advisors, collaborators, and cancer patients; all working together to pioneer a unique approach toward conquering cancer. It is laser-focused and unstoppable in its mission to deliver a new class of medicines to patients and their families to bring them years to life and life to years.

FogPharma

Medical Director / Senior Medical Director, Clinical Development

Deep Lens focuses on enabling faster recruitment of cancer patients for clinical trials at the time of diagnosis.

Deep Lens is a provider of a digital pathology workflow platform intended to allow pathology groups to collaborate on groundbreaking cancer research. The company's platform includes AI-powered image detection and workflow support, collaboration, cloud storage, and built-in APIs for the ingestion of third-party AI models and integration to EMR, LIMS, and other systems, helping patients, pathologists, and physicians work together to accelerate and optimize treatment. Founded in 2017, Deep Lens is headquartered in Columbus, Ohio.

Location

Company Stage

Age of Data

Experience

Industry

Company